Why the study?
Does metformin with or without vitamin E reduce cardiac injury in rats with isoproterenol-induced myocardial infarction?
Does metformin with or without vitamin E reduce cardiac injury in rats with isoproterenol-induced myocardial infarction?
Metformin, alone or in combination with vitamin E, exerts cardioprotective effects against isoproterenol-induced myocardial infarction in rats via antioxidant activity and NF-κB modulation.
May warrant caution against clinical use in myocardial infarction; leaves open translation from rat models to human trials.
Several studies have reported that metformin is cardioprotective for diabetic and non-diabetic ischemic hearts through mechanisms that cannot be entirely attributed to its anti-hyperglycemic effect. This study was designed to investigate the cardioprotective effects of metformin with and without vitamin E after induction myocardial infarction (MI) in rats, using isoproterenol. Administration of metformin or vitamin E significantly reduced the cardiac mass index (P < 0.01), ameliorated the changes to cardiac biomarkers, and attenuated oxidative stress levels compared to the isoproterenol group. Interestingly, combination therapy showed a slight synergistic effect. Histopathological analysis suggested that metformin treatment reduced NF-κB expression and protected against isoproterenol-induced MI. Our results indicate that metformin mediates a cardioprotective effect against isoproterenol-induced MI via antioxidant activity and modulation of the NF-κB signaling pathway. This suggests that metformin would be beneficial in MI treatment.
No takes yet. Share an insight, caveat, or question.
Al‐Rasheed et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: